Results · Apr-Jun 2026
Onesource Specialty Pharma Q1 FY27 results
Sales grew 37% to ₹449 crore from ₹327 crore in Apr-Jun 2025.
Operating profit grew 39% to ₹123 crore, an operating margin of 27.5% (up 0.4 points from a year ago).
Net profit turned positive: ₹25 crore against a loss of ₹0.19 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +5%, net profit +444%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 449.0 | 327.3 | +37% |
| Operating profit (EBITDA) | 123.3 | 88.5 | +39% |
| Operating margin | 27.5% | 27.0% | +0.4 pts |
| Net profit | 25.0 | -0.2 | turns positive |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.